{
    "type": "VariantTherapeuticResponseProposition",
    "predicate": "sensitivity",
    "description": "Treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation",
    "geneContextQualifier": "BRAF",
    "objectTherapeutic": "Tovorafenib [Ojemda]"
}